Previous Article | Next Article 
Infection and Immunity, July 2001, p. 4407-4416, Vol. 69, No. 7
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.7.4407-4416.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Deletion of wboA Enhances Activation of
the Lectin Pathway of Complement in Brucella abortus and
Brucella melitensis
Carmen M.
Fernandez-Prada,1,*
Mikeljon
Nikolich,1
Ramesh
Vemulapalli,2
Nammalwar
Sriranganathan,2
Stephen M.
Boyle,2
Gerhardt G.
Schurig,2
Ted L.
Hadfield,3 and
David
L.
Hoover1
Department of Bacterial Diseases, Walter Reed
Army Institute of Research,1 and
Department of Microbiology, Armed Forces Institute of
Pathology,3 Washington, D.C. 20307, and
Center for Molecular Medicine and Infectious Diseases,
Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg,
Virginia 240612
Received 7 November 2000/Returned for modification 18 January
2001/Accepted 12 April 2001
 |
ABSTRACT |
Brucella spp. are gram-negative intracellular pathogens
that survive and multiply within phagocytic cells of their hosts. Smooth organisms present O polysaccharides (OPS) on their surface. These OPS help the bacteria avoid the bactericidal action of serum. The
wboA gene, coding for the enzyme glycosyltransferase, is
essential for the synthesis of O chain in Brucella. In this
study, the sensitivity to serum of smooth, virulent Brucella
melitensis 16M and B. abortus 2308, rough
wboA mutants VTRM1, RA1, and WRR51 derived from these two
Brucella species, and the B. abortus vaccine
strain RB51 was assayed using normal nonimmune human serum (NHS). The
deposition of complement components and mannose-binding lectin (MBL) on
the bacterial surface was detected by flow cytometry. Rough B. abortus mutants were more sensitive to the bactericidal action of
NHS than were rough B. melitensis mutants. Complement
components were deposited on smooth strains at a slower rate compared
to rough strains. Deposition of iC3b and C5b-9 and bacterial killing
occurred when bacteria were treated with C1q-depleted, but not with
C2-depleted serum or NHS in the presence of Mg-EGTA. These results
indicate that (i) OPS-deficient strains derived from B. melitensis 16M are more resistant to the bactericidal action of
NHS than OPS-deficient strains derived from B. abortus
2308, (ii) both the classical and the MBL-mediated pathways are
involved in complement deposition and complement-mediated killing of
Brucella, and (iii) the alternative pathway is not
activated by smooth or rough brucellae.
 |
INTRODUCTION |
The complement system represents an
important defense mechanism against microorganisms. There are three
pathways by which the complement system can be activated: (i) the
classical pathway, which is initiated by binding of C1q to the Fc
regions of antigen-antibody complexes or directly to pathogenic
bacteria (15, 37); (ii) the alternative pathway, which is
an antibody-independent route initiated by certain structures on the
surface of microorganisms; and (iii) the lectin pathway, which is
initiated by the binding of mannose-binding lectin (MBL) to
carbohydrates on microbial surfaces (33, 37, 43, 46, 47).
MBL and another collectin, pulmonary surfactant protein A (SP-A), can
trigger cellular responses in a manner similar to that of C1q
(15, 39). After activation, complement can effectively
eliminate microorganisms by deposition of proteins onto the microbial
surface, which will (i) serve as opsonins (C1q, C3b or iC3b, and C4b),
providing immune recognition of those organisms by phagocytic cells,
and (ii) lead to the formation and assembly of the membrane attack
complex (MAC or C5b-9), causing the direct lysis of those
microorganisms (15, 16, 26, 44). However, microbial
pathogens have developed effective strategies to avoid recognition or
eradication by complement (56). Avoidance structures of
pathogenic microorganisms include lipopolysaccharides (LPS), outer
membrane proteins (OMP), capsules, porins, and several proteins sharing
molecular mimicry of host complement proteins (1, 2, 11, 25, 27,
28, 31, 32, 34, 42, 48, 56).
Brucella spp. are gram-negative intracellular pathogens,
which can survive and multiply within phagocytic cells of their hosts and are resistant to the bactericidal action of serum. Treatment of
virulent Brucella with normal nonimmune human serum (NHS)
does not result in complement-mediated killing but enhances their
ingestion by macrophages (41). The genus
Brucella consists of six species, each one with a preference
for a host and with differences in pathogenicity: Brucella
abortus (cattle), B. melitensis (goats), B. canis (dogs), B. ovis (sheep), B. suis
(swine), and B. neotomae (desert rat) (41).
However, at the DNA level this genus is a highly homogeneous group that
has been proposed to be only one genomic species (52).
B. abortus and B. melitensis constitute the main
pathogenic species for humans worldwide. These two species may occur as
either smooth or rough variants depending on the expression of O
polysaccharides (OPS) as a component of the bacterial outer membrane
LPS. In rough strains, the expression of OPS is limited or absent and
the attenuation of virulence is generally observed (3, 9, 19,
29). Curiously, B. ovis and B. canis are
two naturally rough Brucella species that are fully virulent in their primary host despite their lack of surface O antigen (4,
5, 19). The O antigen of B. abortus and B. melitensis is a homopolymer of perosamine
(4,6-dideoxy-4-formamido-D-mannopyranosyl), which exists in
two different configurations. The A (abortus) antigen is a linear
homopolymer of
1,2-linked-perosamine. The M (melitensis) antigen is
a linear homopolymer of the same sugar in which four
1,2-linked-perosamine residues are
1,3-linked to the last
monosaccharide of a pentasaccharide repeating unit (22,
23). Although A and M antigens may be present alone or together
on either B. abortus or B. melitensis, strain
2308 expresses almost exclusively A antigen and strain 16M expresses M
antigen (30). B. melitensis, the principal
cause of human brucellosis (55, 57), differs from B. abortus in virulence and cell envelope (17, 58).
Previous studies using bovine serum (17) and NHS (58) have suggested that B. melitensis is more
resistant than B. abortus to the bactericidal action of
complement, although the mechanisms of this enhanced resistance are
unknown. Smooth strains of B. abortus are more resistant
than rough strains to serum bactericidal activity (9, 12,
13). Although this difference has plausibly been attributed to
the lack of surface OPS in rough strains, the strains used in these
studies were not genetically characterized, and the contribution of
other components beside OPS to the resistance of smooth strains could
not be rigorously excluded. The aim of this study was to investigate
the bactericidal activity and complement activation pathways of NHS
against smooth, virulent B. melitensis 16M and B. abortus 2308 and rough mutant strains derived from these two
Brucella species by interrupting the wboA gene,
which is required for O-chain synthesis (29). Bacteria
were treated with NHS at different concentrations and incubation times,
and bacterial survival was then determined. Additionally, deposition of
complement components (C1q, C2, C4, iC3b, and C5b-9) and MBL on the
bacterial surface was detected using a novel flow cytometric technique.
Finally, to elucidate the complement pathways involved in killing or
opsonization of Brucella, bacteria were treated with sera
depleted of C1q or C2 or preincubated with Mg-EGTA prior to
determination of bacterial survival and complement deposition. These
studies demonstrated that (i) OPS-deficient strains derived from
B. melitensis 16M are more resistant to the bactericidal
action of NHS than OPS-deficient strains derived from B. abortus 2308, (ii) both the classical and the MBL-mediated
pathways are involved in complement deposition and complement-mediated
killing of Brucella, and (iii) the alternative pathway is
not activated by smooth or rough brucellae. Smooth brucellae may limit
complement deposition on their surface to protect them from
extracellular killing but allow sufficient deposition to opsonize them
for uptake by macrophages, their preferred target for intracellular replication.
 |
MATERIALS AND METHODS |
Bacterial strains.
The Brucella strains used in
these experiments are listed in Table 1.
Rough strains RB51 and RA1 are wboA mutants derived from
B. abortus 2308 (29). The wboA gene,
previously called rfbU, codes for the enzyme
glycosyltransferase, which is essential for the synthesis of O chain in
Brucella. Strain RA1 was derived from B. abortus
2308 by transposon (Tn5) disruption of the wboA gene (55). Strain RB51 is devoid of the O chain and arose
spontaneously after multiple passages (40); an
IS711 element interrupts the wboA gene in this
strain (50). RB51 contains at least one additional mutation, but the exact nature of the mutation(s) remains unknown (41, 50, 51). Strain VTRM1 was derived from B. melitensis 16M by transposon (Tn5) disruption of the
wboA gene (55). Strain WRR51 was derived from
B. melitensis 16M by replacement of the internal region of
the wboA gene with an antibiotic resistance cassette
(M. P. Nikolich, unpublished results). Strain WRR51/pRFBUK11 was
derived by electroporating pRFBUK11 into strain WRR51. This procedure
complemented the wboA gene and restored the smooth phenotype (Nikolich, unpublished). Bacteria were grown at 37°C with shaking in
Brucella broth (Difco).
Sera.
NHS was obtained from members of the laboratory staff
and stored at
70°C until required. Sera were negative for
Brucella antibody by agglutination tests. Sera depleted of
either C1q or C2 were purchased from Quidel Corp. (San Diego, Calif.).
For inactivation of the classical and MBL-mediated pathways of
complement activation, EGTA (Sigma Chemical Co., St. Louis, Mo.) and
MgCl2 (10 mM) were added as described previously
(38). To inactivate complement completely, sera were
heated at 56°C for 30 min as described elsewhere (38).
Bactericidal assay.
Brucella strains were grown
to mid-logarithmic phase, collected by centrifugation, washed in 0.9%
NaCl, recentrifuged, and suspended in RPMI 1640 medium (RPMI) at
approximately 106 CFU/ml. Next, 100 µl of these
suspensions was transferred into each well in a 96-well plate
containing 100 µl of either fresh (i.e., frozen at
70°C) or
heat-inactivated NHS. The plates were incubated at 37°C for different
times in a CO2 incubator. At each time point, 10-µl
samples were transferred to another 96-well plate in which each well
contained 90 µl of RPMI to make serial dilutions. Two or three
10-µl samples were spot plated from each well onto
Brucella agar, and the plates were incubated at 37°C in a
CO2 incubator for 3 days. CFU were enumerated; duplicate or
triplicate spots were averaged.
Antibodies.
Mouse monoclonal antibodies (MAb) to human
antigens C1q, iC3b, C4, SC5b-9, factor B, and factor H, and goat
polyclonal antiserum to human C2 were purchased from Quidel Corp. Mouse
MAb to human MBL was purchased from Statens Serum Institut, Copenhagen,
Denmark. Fluorescein isothiocyanate (FITC)-conjugated goat anti-murine immunoglobulin G (IgG) and FITC-conjugated rabbit anti-goat antibody (heavy and light chain specific) were purchased from Sigma.
Flow cytometry.
Brucella strains were harvested
from 24-h broth cultures and washed once with 0.9% NaCl. Bacterial
suspensions were adjusted turbidometrically to a concentration of
107 CFU/ml in RPMI and incubated in 2, 3, or 10% serum for
different periods of time at 37°C in a CO2 incubator.
Then, 100 µl of these suspensions was transferred to a 96-well filter
plate set on a filter unit. The samples were next washed three times
with 300 µl of phosphate-buffered saline (Gibco) containing 0.1%
bovine serum albumin (PBS-BSA) and resuspended in 100 µl of PBS-BSA. Complement antibodies were added at a concentration of 20 µg/ml in
PBS-BSA; nonspecific staining and unstained controls received PBS-BSA
only. The plate was incubated at 4°C for 30 min (18). After washing and resuspending the samples as before, secondary, FITC-conjugated anti-murine IgG or anti-goat IgG antibody or PBS-BSA (for unstained controls) was added, and the plate was again incubated at 4°C for 30 min. Finally, samples were washed as before and fixed
in 300 µl of 4% formaldehyde in PBS. Controls were cells either
unstained or stained only with the secondary antibody. An aliquot of
each sample was plated on Brucella agar plates and incubated
for 3 days at 37°C in a CO2 incubator for sterility check. Samples were then acquired on Becton Dickinson FACSort flow
cytometer and analyzed using CellQuest software (Becton Dickinson, Mountain View, Calif.).
Elution of complement from bacterial surface.
Brucella strains were incubated with serum as outlined
above, but bacteria were treated for 30 min at 37°C with 1 M NaCl in RPMI with 0.15 mM CaCl2 and 1.0 mM MgCl2
(14) before the samples were transferred to a 96-well
filter plate set for staining for flow cytometry.
Statistical analysis.
Statistical analysis was done by
Student's t test using INSTAT statistical analysis package
(Graph Pad Software, Inc., San Diego, Calif.). The significance was
P < 0.05.
 |
RESULTS |
Bactericidal effect of NHS on Brucella strains.
NHS was tested for its ability to kill the rough and smooth B. abortus and B. melitensis strains listed in Table 1 and
described into Materials and Methods. As shown in Fig.
1, only rough B. abortus
strains RB51 and RA1 were sensitive to the bactericidal action of
serum. However, differences between these two rough B. abortus strains were detected. We found that 10% fresh NHS killed
more than 2 log10 of RB51 in 4 h but only reduced RA1 by 1 log10 (Fig. 1A). Similar incubation with 50% NHS for
4 h led to 3.7 log10 reduction in RB51 but only 1.7 log10 reduction in RA1 (Fig. 1B). These differences were
maintained even when the incubation period was extended to 24 h
(Fig. 1). Strains RB51 and RA1 both multiplied nearly 10-fold when
cultured with heated serum for 24 h, but 10 or 50% fresh serum reduced
RB51 by more than 4 log10 from the starting inoculum and
reduced RA1 by more than 3 log10. In contrast to this
marked susceptibility of rough B. abortus to the
bactericidal activity of NHS, rough B. melitensis strains
VTRM1 and WRR51 were not killed by 10% or even 50% fresh serum. CFU
counts were similar at all time points regardless of whether rough
strains were incubated with fresh or heat-inactivated serum. Moreover,
they multiplied as well as the smooth, wild-type strains 2308 (Fig. 1)
or 16M or the smooth, complemented strain WRR51/pRFBUK11. These data
imply that there are additional factors, beside the disruption of gene
wboA, that mediate the varied sensitivity of these two
Brucella species to the bactericidal action of serum.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 1.
Bactericidal effect of 10% (A) and 50% (B) NHS on
rough and smooth B. abortus and B. melitensis
strains. Bacteria were grown overnight at 37°C and incubated in fresh
NHS (F) or heated serum (H) as described in Materials and Methods. The
data represent the number of CFU/milliliter recovered at the initial
time and after 4 and 24 h of incubation. The characteristics of the
strains are listed in Table 1. *, Not significant P values
compared to their respective CFU recovered after incubation with heat
serum. Error bars show the means ± the standard deviations (SD).
**, CFU/milliliter lower than 100 were not detected by the plating
technique described in Materials and Methods.
|
|
Deposition of complement components on the surface of smooth and
rough Brucella strains.
In preliminary experiments, we
found that an NHS concentration of 2 to 3% and a treatment period of 1 to 2 h were optimal for flow cytometric detection of all
complement proteins except C1q and MBL; these required a shorter
treatment period and sometimes a higher NHS concentration in order to
detect their binding to the bacterial surface (data not shown). In the
experiment shown in Fig. 2, bacteria were
exposed to 3% NHS and immediately fixed with formaldehyde. Rough
Brucella strains (RB51, RA1, VTRM1, and WRR51) bound more
MBL and C1q on their surface than smooth organisms (2308, 16M, and
WRR51/pRFBUK11). Similarly rough strains bound more iC3b and C5b-9 than
smooth strains (Fig. 3). These
experiments also suggested that B. melitensis strains bound
less complement than B. abortus strains. This suggestion was
confirmed by experiments in which bacteria were treated with 2% serum
and the binding of iC3b and C5b-9 was determined (Fig.
4). At that serum concentration, VTRM1
and WRR51 bound less iC3b (P < 0.008) and C5b-9 (P < 0.01) than either RB51 or RA1. Strain 16M bound slightly less of
these components than strain 2308.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
Comparative complement deposition on smooth (A to C) and
rough (D to G) B. abortus (C, F, and G) and B. melitensis (A, B, D, and E) strains. Bacteria were fixed with
formaldehyde immediately after the addition of 3% fresh NHS (F) or
heated serum (H). The binding of MBL (gray line) and C1q (black line)
to bacteria was detected by incubation with the corresponding MAb and
secondary FITC-labeled antibodies as described in Materials and
Methods. The respective nonspecific binding (NSB) is shown in the
shaded area. Cells were analyzed on a FACSort flow cytometer (Becton
Dickinson). The panels show the results for 16M (A), WRR51/pRFBUK11
(B), 2308 (C), WRR51 (D), VTRM1 (E), RA1 (F), and RB51 (G). The
characteristics of the strains are listed in Table 1. These data are
from a representative experiment that was repeated with similar
results.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
Comparative complement deposition on smooth (A to C) and
rough (D to G) B. abortus (C, F, and G) and B. melitensis (A, B, D, and E) strains. Bacteria were incubated in
3% fresh NHS or heated serum. Binding of iC3b (gray line) and C5b-9
(black line) to bacteria was detected by incubation with the
corresponding MAb and secondary FITC-labeled antibodies as described in
Materials and Methods. The respective nonspecific binding (NSB) is
shown in the shaded area. Cells were analyzed on a FACSort flow
cytometer (Becton Dickinson). The panels show results for 16M (A),
WRR51/pRFBUK11 (B), 2308 (C), WRR51 (D), VTRM1 (E), RA1 (F), and RB51
(G). The characteristics of the strains are listed in Table 1. These
data are from a representative experiment that was repeated with
similar results.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Comparative complement deposition between smooth and
rough B. abortus and B. melitensis strains using
2% NHS. Bacteria were incubated and treated as described in the legend
to Fig. 2. Here, deposition of iC3b and C5b-9 on each strain was
compared using 2% fresh NHS. The rough B. abortus strains,
RB51 and RA1, deposited more iC3b (*, P<0.008) and C5b-9
(**, P < 0.01) than the rough B. melitensis strains, VTRM1 and WRR51. Error bars show the
means ± the SD of two different experiments. The characteristics
of the strains are listed in Table 1.
|
|
These data suggested that differences in susceptibility to bactericidal
activity in serum between rough and smooth strains and between B. melitensis and B. abortus might be due to differences in the quantity of complement components bound to the cell surface, particularly to the quantity of bound C5b-9, the MAC. It was also possible, however, that the MAC bound less tightly in resistant strains
than in susceptible strains, as previously demonstrated in other
microorganisms (14, 27). To address this latter
possibility, we examined the susceptibility to elution by 1 M NaCl.
Bacteria were treated with 10% NHS for 30 min and then incubated with
1 M NaCl for an additional 30 min. Cells were stained for complement components and analyzed by flow cytometry. A total of 85% of bound C5b-9 was eluted from the surface of 16M and 72% was eluted from 2308 by treatment with 1 M NaCl. In contrast, this treatment with 1 M NaCl
eluted only 10 to 20% of C5b-9 from the surface of rough strains.
These studies indicated that the C5b-9 complex was not attached by
strong hydrophobic interactions to the cell surface of smooth
Brucella.
Complement pathways involved.
To determine the complement
pathways involved in killing of rough B. abortus strains, we
treated bacteria with nonimmune human serum depleted of certain
complement components. C1q-depleted serum was used to determine whether
only the classical pathway was involved. C2-depleted serum was included
to determine if MBL also played a role in the killing of these
bacteria. To determine the role of the alternative pathway, we treated
some of these sera and NHS with Mg-EGTA, which inhibits the classical
and collectin pathways but not the alternative pathway. Sera heated at
56°C for 30 min were used as controls, since this procedure
inactivates complement completely. When C1q-depleted serum was used,
the deposition of iC3b and C5b-9 was identical to the deposition when
fresh NHS was used (Fig. 5), and the
bactericidal activity of C1q-depleted serum (1 log10
reduction in 2 h) was identical to that of NHS (Fig.
6). In contrast, the use of C2-depleted
serum resulted in a dramatic reduction in the binding of anti-iC3b
(P = 0.014) and anti-C5b-9 (P = 0.008)
(Fig. 5) and in almost complete inhibition of killing (Fig. 6).
Furthermore, when C1q- or C2-depleted serum was treated with Mg-EGTA
(to eliminate the classical and MBL pathways) or heated at 56°C for
30 min (to eliminate all complement activity), deposition of these two
components (Fig. 5) and bacterial killing (Fig. 6) were completely
abolished. Taken together, these data indicated that the alternative
pathway did not mediate bacterial killing and that another,
nonclassical pathway was playing a role. This possibility was confirmed
by treating strain RB51 with 10% NHS and processing the cells for
staining with anti-MBL and antibodies to other complement components
either immediately or after 1 h of incubation. MBL, as well as
C1q, were deposited very early on the surface of this strain. However,
the amounts detected remained low or decreased after 1 h of
incubation (Fig. 7).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
Use of C1q- and C2-depleted NHS for complement pathway
determination. Complement deposition of iC3b and C5b-9 on rough
B. abortus strain RB51 was determined using fresh NHS, sera
depleted of either C1q or C2, and depleted sera treated with Mg-EGTA as
described in Materials and Methods. Cells were analyzed on a FACSort
flow cytometer, and their respective mean fluorescence was compared to
that obtained with fresh NHS and is shown as percentage. *,
P < 0.03 compared to fresh NHS. Error bars show the
means ± the SD of two different experiments.
|
|

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 6.
Use of C1q- and C2-depleted NHS for complement pathway
determination. Bactericidal assays were done by incubating the rough
B. abortus RB51 strain with fresh NHS, C1q- and C2-depleted
sera, depleted sera treated (T) with Mg-EGTA, and heat-depleted sera.
The data represent the number of CFU/milliliter recovered at the
initial time and after 2 h of incubation. *, Not significantly
different from the number of CFU recovered after incubation with fresh
NHS. Error bars show the SD from triplicate samples.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 7.
Classical and MBL-mediated pathways are involved in
complement deposition on Brucella surfaces. RB51 was
incubated with fresh NHS for different periods of time. Binding of
complement components to bacteria was detected by staining and flow
cytometric analysis. (A) Deposition of MBL, C1q, and C4d. (B)
Deposition of iC3b and C5b-9. Note the difference in scale between
panels A and B. Error bars show the means ± the SD of values from
two different experiments.
|
|
 |
DISCUSSION |
In the present study, we compared the deposition of complement
components and the complement-mediated killing of smooth and rough
mutants of B. abortus and B. melitensis. Although
differences in susceptibility to serum between these two species
(17, 58) and the role of O antigen in the resistance of
Brucella to complement-mediated killing have been reported
previously, most of these studies have been done using fortuitously
isolated rough variants (9, 12, 13, 36). More recent work
with genetically defined rough mutants has focused on understanding the
effect of alterations in the synthesis of OPS on Brucella
virulence, i.e., survival in macrophages and mice, but little or no
information on the interactions of complement with these strains is
available (3, 19, 29, 36, 55). RA1 and VTRM1, two rough
mutant strains used in this study, were derived from virulent B. abortus 2308 or B. melitensis 16M, respectively
(29, 55). Both rough mutants are defective only in the
wboA gene encoding the enzyme glycosyltransferase. This gene
is essential for the synthesis of O side chain in smooth strains of
Brucella (29). Although strains RA1 and VTRM1
have identical mutations, RA1 strain was more sensitive to the
bactericidal action of NHS, and more complement components were
deposited on its surface than on strain VTRM1 (Fig. 1 to 4). Similar
species-specific differences in both complement deposition and
complement-mediated killing were also observed when strain RA1 was
compared with another rough mutant of B. melitensis, WRR51
(Fig. 1 to 4). Strain WRR51 was derived from B. melitensis
strain 16M by replacement of the internal region of the wboA
gene with an antibiotic resistance cassette (Nikolich, unpublished)
instead of having a transposon insertion on this gene, as in the case
of VTRM1 or RA1 (55). There were no significant
differences in either complement deposition or killing between VTRM1
and WRR51. Both strains were less susceptible than RA1 to the
deposition of complement and complement-mediated killing. The vaccine
strain RB51, a highly attenuated rough mutant derived by repeated in
vitro passage of 2308 (40), was even more sensitive to the
killing action of serum and deposited more complement components on its
surface than RA1. Strains VTRM1 and WRR51 are attenuated in mice
(55; Nikolich, unpublished), but not as much as strains
RB51 or RA1 (23, 29, 41, 55). The reasons for the greater
attenuation of RB51 are unknown but may be related to more profound
deficiencies in OPS. In addition to a defect in wboA
(50), RB51 also carries mutations in other gene(s)
necessary for the expression of a smooth phenotype (51). Recently, McQuiston et al. have compared the LPS of strains RA1 and
RB51 with the LPS of strain 2308 (29). Silver staining
indicated that no O side chain was associated with LPS of strains RA1
or RB51, and compositional analysis of smooth and rough B. abortus LPS revealed that
2-keto-3-deoxy-D-manno-2-octulosonic acid (KDO) was the
predominant glycose in the rough LPS (29). However, more
mannose, galactose, and quinovosamine were found in RA1 than in RB51,
suggesting than some components of the O side chain may be present in
RA1 (29). It remains to be determined whether the
differences between these glycoses are responsible for the complement-related differences observed in the present study and for
the differences in virulence reported previously (29).
Our flow cytometric assays revealed that, in addition to depositing
less complement on their surface, smooth strains of both B. abortus and B. melitensis released MAC quite readily
(72 and 85%, respectively) when treated with 1 M NaCl as described for other serum-resistant organisms (14, 27). As previously
shown with Aspergillius (21), Trypanosoma
cruzi (45), Borrelia burgdorferi (6), Yersinia enterocolitica (34),
and Helicobacter pylori (38), the diminished
binding of complement components seems to be related to pathogenicity.
It is possible that the increased virulence of rough B. melitensis compared to B. abortus strains for mice is
related to decreased susceptibility to complement-mediated lysis. This
decreased susceptibility in turn may be due to reduced deposition of
complement components on the bacterial surface, since we did not detect
differences between rough B. melitensis and B. abortus in the strength of the MAC attachment. It is possible that
differences in the strength of the MAC attachment exist but were not
detectable by the method used. It is also possible that other
interactions of complement components with the bacterial membrane may
mediate the differences in susceptibility to lysis between rough
B. melitensis and B. abortus strains.
We speculate that these differences may be related to differential
expression of OMP in the two species. Although the genus Brucella is highly homogeneous at the DNA level
(52), major differences and diversity among
Brucella species are found in the major OMP. OMP are exposed
on the bacterial surface but are less accessible to complement in
smooth strains than in rough strains (8, 13, 31, 32). Both
the OPS length and the proportion of S-LPS on the bacterial surface
influence the ability to shield bacteria from complement-mediated
killing (4, 31, 32). Brucella OMP have been
classified according to their apparent molecular mass as major 25- to
30-kDa, 31- to 34-kDa, and 36- to 38-kDa proteins and minor 10-, 16-, 19-, and 89-kDa proteins (5). Interestingly, the OMP of 31 to 34 kDa is tightly associated with the peptidoglycan and is the most
exposed OMP in smooth B. melitensis and B. suis
strains (8, 28). Remarkably, no binding of anti-31- to
34-kDa OMP MAb to B. abortus strains is detected by
immunoblotting (53), enzyme-linked immunosorbent assay,
flow cytometry, or immunoelectron microscopy assays (5,
28). Furthermore, hybridization studies have shown that the
omp-31 gene is absent in B. abortus strains
(54). This gene is included in a multigenic, 10-kb segment
present in B. suis, B. melitensis, B. ovis, and B. canis but lacking in B. abortus (8, 54).
This observation raises several intriguing questions in view of our
findings in the present report. Does OMP-31 or perhaps another
product(s) of this 10-kb region play a role in resistance to the
bactericidal action of complement observed in both rough and smooth
strains of B. melitensis? If so, is this resistance an
important determinant of pathogenicity not only for B. melitensis but for other brucellae as well? We plan to address
these issues in further studies.
Our findings indicate that binding of iC3b and C5b-9 to the
Brucella surface is mediated primarily through the classical
and MBL-mediated pathways without activation of the alternative
pathway. These results are consistent with previous studies
demonstrating that the bactericidal action of serum against B. abortus is due to effects of the classical and not the alternative
pathway (9, 13, 22, 23). In addition, our results provide
evidence for the first time that MBL may also play a role in host
defense against Brucella. MBL has been increasingly
recognized as a key protein in innate immunity (7, 10, 20, 24,
35, 46, 47, 49). A member of the collectin family, MBL is
structurally related to C1q, the first subcomponent of the classical
complement pathway, and to SP-A (24, 39, 46, 47, 49). The
collectins are characterized by the presence of two major domains: a
collagen-like and a lectin domain. The lectin domain of MBL mediates
binding to carbohydrates on microorganisms. Consequent conformational changes in the collagen-like domains induce C4-converting activity, and
complement activation proceeds via C4 and C2 as in the classical pathway (20, 24, 43, 46, 47). In our studies, the absence of iC3b on bacteria incubated with C2-depleted serum and the presence of iC3b on bacteria incubated with C1q-deficient serum indicate that
deposition of MBL plays a functional role in complement activation on
Brucella. C1q does not have a lectin domain and, for that
reason, sugar-binding activity is not observed. However, in addition to its well-known ability to bind to immunoglobulin Fc regions in antigen-antibody complexes, C1q can also bind directly to pathogenic bacteria (15). In our study, using nonimmune serum, C1q
and MBL both deposited more readily on the surface of rough
Brucella than on smooth Brucella. However, the
intensity of their binding was very low compared to other complement
components (Fig. 6). This may reflect the amplification characteristics
of the complement cascade: one C142 or presumably the analogous
MBL-containing complex can activate numerous C3 molecules.
These studies make three important points. First, the amount of
complement deposition and/or strength of association of the MAC with
the bacterial surface are important determinants of the ability of
serum to kill Brucella. Second, the presence of OPS on the
bacterial surface cannot be the only factor causing the inhibition of
binding of complement components observed in the more virulent
organisms. Third, MBL and C1q both initiate antibody-independent complement activation and brucellacidal activity. Further
investigations are needed to define the role of MBL in the immune
response to Brucella. Collectins not only activate
complement but may also influence cellular activation via specific
receptors on macrophages and other immune effectors. The interactions
of complement components, Brucella, and macrophages are an
intriguing subject for additional studies.
 |
ACKNOWLEDGMENT |
We thank Elzbieta Zelazowska for practical advice with the flow data.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Bacterial Diseases, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Bldg. 503, Rm. 2N57,
Washington, DC 20307-5100. Phone: (301) 319-9658. Fax: (301) 319-9123. E-mail: Carmen.Fernandez-Prada{at}NA.AMEDD.ARMY.MIL.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Alberti, S.,
D. Alvarez,
S. Merino,
M. T. Casado,
F. Vivanco,
J. M. Tomas, and V. J. Benedi.
1996.
Analysis of complement C3 deposition and degradation on Klebsiella pneumoniae.
Infect. Immun.
64:4726-4732[Abstract].
|
| 2.
|
Alberti, S.,
G. Marques,
S. Hernandez-Alles,
X. Rubires,
J. M. Tomas,
F. Vivanco, and V. J. Benedi.
1996.
Interaction between complement subcomponent C1q and the Klebsiella pneumoniae porin OmpK36.
Infect. Immun.
64:4719-4725[Abstract].
|
| 3.
|
Allen, C. A.,
L. G. Adams, and T. A. Ficht.
1998.
Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival.
Infect. Immun.
66:1008-1016[Abstract/Free Full Text].
|
| 4.
|
Bowden, R. A.,
A. Cloekaert,
M. S. Zygmunt,
S. Bernard, and G. Dubray.
1995.
Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry.
Infect. Immun.
63:3945-3952[Abstract].
|
| 5.
|
Bowden, R. A.,
A. Cloekaert,
M. S. Zygmunt,
S. Bernard, and G. Dubray.
1995.
Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis.
J. Med. Microbiol.
43:344-347[Abstract].
|
| 6.
|
Breitner-Ruddock, S.,
R. Wurzner,
J. Schulze, and V. Brade.
1997.
Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi.
Med. Microbiol. Immunol.
185:253-60[CrossRef][Medline].
|
| 7.
|
Carroll, M. C.
1998.
The role of complement and complement receptors in induction and regulation of immunity.
Annu. Rev. Immunol.
16:545-568[CrossRef][Medline].
|
| 8.
|
Cloeckaert, A.,
J. Verger,
M. Grayon, and N. Vizcaino.
1996.
Molecular and immunological characterization of the major outer membrane proteins of Brucella.
FEMS Microbiol. Lett.
145:1-8[CrossRef][Medline].
|
| 9.
|
Corbeil, L. B.,
K. Blau,
T. J. Inzana,
K. H. Nielsen,
R. H. Jacobson,
R. R. Corbeil, and A. J. Winter.
1988.
Killing of Brucella abortus by bovine serum.
Infect. Immun.
56:3251-3261[Abstract/Free Full Text].
|
| 10.
|
Chaka, W.,
A. F. M. Verheul,
V. V. Vaishnav,
R. Cherniak,
J. Scharringa,
J. Verhoef,
H. Snippe, and A. I. M. Hoepelman.
1997.
Induction of TNF- in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein.
J. Immunol.
159:2979-2985[Abstract].
|
| 11.
|
China, B.,
M. P. Sory,
B. T. N'guyen,
M. de Bruyere, and G. R. Cornelis.
1993.
Role of the YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules.
Infect. Immun.
61:3129-3136[Abstract/Free Full Text].
|
| 12.
|
Eisenschenk, F. C.,
J. J. Houle, and E. M. Hoffmann.
1995.
Serum sensitivity of field isolates and laboratory strains of Brucella abortus.
Am. J. Vet. Res.
56:1592-1598[Medline].
|
| 13.
|
Eisenschenk, F. C.,
J. J. Houle, and E. M. Hoffmann.
1999.
Mechanism of serum resistance among Brucella abortus isolates.
Vet. Microbiol.
68:235-244[CrossRef][Medline].
|
| 14.
|
Egan, A. M., and D. L. Gordon.
1996.
Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes.
Infect. Immun.
64:4952-4959[Abstract].
|
| 15.
|
Eggleton, P.,
K. B. M. Reid, and A. J. Tenner.
1998.
C1q-how many functions? How many receptors?
Trends Cell Biol.
8:428-431[CrossRef][Medline].
|
| 16.
|
Esser, A. F.
1994.
The membrane attack complex of complement: assembly, structure and cytotoxic activity.
Toxicology
87:229-247[CrossRef][Medline].
|
| 17.
|
Gallego, M. C., and M. A. LaPena.
1990.
The interaction of Brucella melitensis 16-M and caprine polymorphonuclear leukocytes.
Comp. Immun. Microbiol. Infect. Dis.
13:59-65[CrossRef][Medline].
|
| 18.
|
Gemmell, C. H.
1997.
A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces.
J. Biomed. Mater. Res.
37:474-480[CrossRef][Medline].
|
| 19.
|
Godfroid, F.,
B. Taminiau,
I. Danese,
P. Denoel,
A. Tibor,
V. Weynants,
A. Cloeckaert,
J. Godfroid, and J. Letesson.
1998.
Identification of the perosamine synthetase gene of Brucella melitensis 16M and involvement of lipopolysaccharide O side chain in Brucella survival in mice and in macrophages.
Infect. Immun.
66:5485-5493[Abstract/Free Full Text].
|
| 20.
|
Hansen, S., and U. Holmskov.
1998.
Structural aspects of collectins and receptors for collectins.
Immunobiology
199:165-189[Medline].
|
| 21.
|
Henwick, S.,
S. V. Hetherington, and C. C. Patrick.
1993.
Complement binding to Aspergillus conidia correlates with pathogenicity.
J. Lab. Clin. Med.
122:27-35[Medline].
|
| 22.
|
Hoffmann, E. M.,
W. L. Kellogg, and J. J. Houle.
1994.
Inhibition of complement-mediated killing of Brucella abortus by fluid-phase immunoglobulins.
Am. J. Vet. Res.
55:810-814[Medline].
|
| 23.
|
Hoffmann, E. M., and J. J. Houle.
1995.
Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host.
Crit. Rev. Microbiol.
21:153-163[Medline].
|
| 24.
|
Holmskov, U.,
R. Malhotra,
R. B. Sim, and J. C. Jensenius.
1994.
Collectins: collagenous C-type lectins of the innate immune defense system.
Immunol. Today
15:67-74[CrossRef][Medline].
|
| 25.
|
Hortsmann, R. D.
1992.
Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.
Infect. Immun.
60:721-727[Free Full Text].
|
| 26.
|
Jack, D. L.,
A. W. Dodds,
N. Anwar,
C. A. Ison,
A. Law,
M. Frosch,
M. W. Turner, and N. J. Klein.
1998.
Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B.
J. Immunol.
160:1346-1353[Abstract/Free Full Text].
|
| 27.
|
Joiner, K. A.,
K. A. Warren,
C. Hammer, and M. M. Frank.
1985.
Bactericidal but not nonbactericidal C5b-9 is associated with distinctive outer membrane proteins in Neisseria gonorrhoeae.
J. Immunol.
134:1920-1925[Abstract].
|
| 28.
|
Kroll, H. P.,
S. Bhakdi, and P. W. Taylor.
1983.
Membrane changes induced by exposure of Escherichia coli to human serum.
Infect. Immun.
42:1055-1066[Abstract/Free Full Text].
|
| 29.
|
McQuiston, J. R.,
R. Vemulapalli,
T. J. Inzana,
G. G. Shurig,
N. Sriranganathan,
D. Fritzinger,
T. L. Hadfield,
R. A. Warren,
N. Snellings,
D. Hoover,
S. M. Halling, and S. M. Boyle.
1999.
Genetic characterization of a Tn5-disrupted glycosyltransferase gene homolog in Brucella abortus and its effect on lipopolysaccharide composition and virulence.
Infect. Immun.
67:3830-3835[Abstract/Free Full Text].
|
| 30.
|
Meikle, P. J.,
M. B. Perry,
J. W. Cherwonogrodzky, and D. R. Bundle.
1989.
Fine structure of A and M antigens from Brucella biovars.
Infect. Immun.
57:2820-2826[Abstract/Free Full Text].
|
| 31.
|
Merino, S.,
X. Rubires,
A. Aguilar,
S. Alberti,
S. Hernandez-Alles,
V. J. Benedi, and J. M. Tomas.
1996.
Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing.
Infect. Immun.
64:5302-5309[Abstract].
|
| 32.
|
Merino, S.,
M. M. Nogueras,
A. Aguilar,
S. Rubieres,
S. Alberti,
V. J. Benedi, and J. M. Tomas.
1998.
Activation of the complement classical pathway (C1q binding) by mesophilic Aeromonas hydrophila outer membrane protein.
Infect. Immun.
66:3825-3831[Abstract/Free Full Text].
|
| 33.
|
Morgan, B. P.
1995.
Physiology and pathophysiology of complement: progress and trends.
Crit. Rev. Clin. Lab. Sci.
32:265-298[Medline].
|
| 34.
|
Pilz, D.,
T. Vocke,
J. Heesemann, and V. Brade.
1992.
Mechanism of YadA-mediated serum resistance of Yersinia enterocolitica serotype O3.
Infect. Immun.
60:189-195[Abstract/Free Full Text].
|
| 35.
|
Polostky, V. Y.,
J. T. Belisle,
K. Mikusova,
R. A. B. Ezekowitz, and K. A. Joiner.
1997.
Interaction of human mannose-binding protein with Mycobacterium avium.
J. Infect. Dis.
175:1159-1168[Medline].
|
| 36.
|
Price, R. E.,
J. W. Templeton, and L. G. Adams.
1990.
Survival of smooth, rough and transposon mutant strains of Brucella abortus in bovine mammary macrophages.
Vet. Immunol. Immunopathol.
26:353-365[CrossRef][Medline].
|
| 37.
|
Robertson, M.
1998.
Innate immunity.
Curr. Biol.
8:R595-R597[CrossRef][Medline].
|
| 38.
|
Rokita, E.,
A. Makristathis,
E. Presterl,
M. L. Rotter, and A. M. Hirschi.
1998.
Helicobacter pylori urease significantly reduces opsonization by human complement.
J. Infect. Dis.
178:1521-1525[CrossRef][Medline].
|
| 39.
|
Sano, H.,
H. Sohma,
T. Muta,
S. Nomura,
D. R. Voelker, and Y. Kuroki.
1999.
Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD14.
J. Immunol.
163:387-395[Abstract/Free Full Text].
|
| 40.
|
Shurig, G. G.,
R. M. Roop II,
T. Bagchi,
S. M. Boyle,
D. Burman, and N. Sriranganathan.
1991.
Biological properties of RB51: a stable rough strain of Brucella abortus.
Vet. Microbiol.
28:171-188[CrossRef][Medline].
|
| 41.
|
Shurig, G. G.
1997.
Brucellosis vaccines: past, present and future, p. 26-34.
In
50th anniversary meeting of brucellosis research conference. IDEXX Laboratories, Inc., Chicago, Ill.
|
| 42.
|
Taylor, P. W., and H. P. Kroll.
1984.
Interaction of human complement proteins with serum-sensitive and serum-resistant strains of Escherichia coli.
Mol. Immunol.
21:609-620[CrossRef][Medline].
|
| 43.
|
Thiel, S.,
T. Vorup-Jensen,
C. M. Stover,
W. Schwaeble,
S. B. Laursen,
K. Poulsen,
A. C. Willis,
P. Eggleton,
S. Hansen,
U. Holmskov,
K. B. M. Reid, and J. C. Jensenius.
1997.
A second serine protease associated with mannan-binding lectin that activates complement.
Nature
386:506-510[CrossRef][Medline].
|
| 44.
|
Tomlinson, S.
1993.
Complement defense mechanisms.
Curr. Opin. Immunol.
5:83-89[CrossRef][Medline].
|
| 45.
|
Tomlinson, S.,
L. C. Pontes de Carvalho,
F. Vandekerckhove, and V. Nussenzqweig.
1994.
Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement.
J. Immunol.
153:3141-3147[Abstract].
|
| 46.
|
Turner, M. W.
1996.
Mannose-binding lectin: the pluripotent molecule of the innate immune system.
Immunol. Today
17:532-540[CrossRef][Medline].
|
| 47.
|
Turner, M. W.
1998.
Mannose-binding lectin (MBL) in health and disease.
Immunobiology
199:327-339[Medline].
|
| 48.
|
Van den Berg, R. H.,
M. C. Faber-Krol,
J. A. M. van de Klundert,
L. A. van Es, and M. R. Daha.
1996.
Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
J. Immunol.
156:4466-4473[Abstract].
|
| 49.
|
Vasta, G. R.,
M. Quesenberry,
H. Ahmed, and N. O'Leary.
1999.
C-type lectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway.
Dev. Comp. Immunol.
23:401-420[CrossRef][Medline].
|
| 50.
|
Vemulapalli, R.,
J. R. McQuiston,
G. G. Schurig,
N. Sriranganathan,
S. M. Halling, and S. M. Boyle.
1999.
Identification of an IS711 element interrupting the wboA gene of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains.
Clin. Diagn. Lab. Immunol.
6:760-764[Abstract/Free Full Text].
|
| 51.
|
Vemulapalli, R.,
Y. He,
L. S. Buccolo,
S. M. Boyle,
N. Sriranganathan, and G. G. Schurig.
2000.
Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation.
Infect. Immun.
68:3927-3932[Abstract/Free Full Text].
|
| 52.
|
Verger, J. M.,
F. Grimont,
P. A. D. Grimont, and M. Grayon.
1985.
Brucella a monospecific genus as shown by deoxyribonucleic acid hybridization.
Int. J. Syst. Bacteriol.
35:292-295[Abstract/Free Full Text].
|
| 53.
|
Vizcaino, N.,
J. M. Verger,
M. Grayon,
M. S. Zygmunt, and A. Cloeckaert.
1997.
DNA polymorphism at the omp-31 locus of Brucella spp.: evidence for a large deletion in Brucella abortus, and other species-specific markers.
Microbiology
143:2913-2921[Abstract].
|
| 54.
|
Vizcaino, N.,
A. Cloeckaert,
M. S. Zygmunt, and L. Fernandez-Lago.
1999.
Molecular characterization of a Brucella species large DNA fragment deleted in Brucella abortus strains: evidence for a locus involved in the synthesis of a polysaccharide.
Infect. Immun.
67:2700-2712[Abstract/Free Full Text].
|
| 55.
|
Winter, A. J.,
G. G. Schurig,
S. M. Boyle,
N. Sriranganathan,
J. S. Bevins,
F. M. Enright,
P. H. Elzer, and J. D. Kopec.
1996.
Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
Am. J. Vet. Res.
57:677-683[Medline].
|
| 56.
|
Wurzner, R.
1999.
Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry.
Mol. Immunol.
36:249-260[CrossRef][Medline].
|
| 57.
|
Young, E. J.
1983.
Human brucellosis.
Rev. Infect. Dis.
5:821-842[Medline].
|
| 58.
|
Young, E. J.,
M. Borchert,
F. L. Kretzer, and D. M. Musher.
1985.
Phagocytosis and killing of Brucella by human polymorphonuclear leukocytes.
J. Infect. Dis.
151:682-690[Medline].
|
Infection and Immunity, July 2001, p. 4407-4416, Vol. 69, No. 7
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.7.4407-4416.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Billard, E., Dornand, J., Gross, A.
(2007). Interaction of Brucella suis and Brucella abortus Rough Strains with Human Dendritic Cells. Infect. Immun.
75: 5916-5923
[Abstract]
[Full Text]
-
Caro-Hernandez, P., Fernandez-Lago, L., de Miguel, M.-J., Martin-Martin, A. I., Cloeckaert, A., Grillo, M.-J., Vizcaino, N.
(2007). Role of the Omp25/Omp31 Family in Outer Membrane Properties and Virulence of Brucella ovis. Infect. Immun.
75: 4050-4061
[Abstract]
[Full Text]
-
Pei, J., Turse, J. E., Wu, Q., Ficht, T. A.
(2006). Brucella abortus Rough Mutants Induce Macrophage Oncosis That Requires Bacterial Protein Synthesis and Direct Interaction with the Macrophage.. Infect. Immun.
74: 2667-2675
[Abstract]
[Full Text]
-
Jimenez de Bagues, M. P., Gross, A., Terraza, A., Dornand, J.
(2005). Regulation of the Mitogen-Activated Protein Kinases by Brucella spp. Expressing a Smooth and Rough Phenotype: Relationship to Pathogen Invasiveness. Infect. Immun.
73: 3178-3183
[Abstract]
[Full Text]
-
Jimenez de Bagues, M. P., Terraza, A., Gross, A., Dornand, J.
(2004). Different Responses of Macrophages to Smooth and Rough Brucella spp.: Relationship to Virulence. Infect. Immun.
72: 2429-2433
[Abstract]
[Full Text]
-
Pei, J., Ficht, T. A.
(2004). Brucella abortus Rough Mutants Are Cytopathic for Macrophages in Culture. Infect. Immun.
72: 440-450
[Abstract]
[Full Text]
-
Rittig, M. G., Kaufmann, A., Robins, A., Shaw, B., Sprenger, H., Gemsa, D., Foulongne, V., Rouot, B., Dornand, J.
(2003). Smooth and rough lipopolysaccharide phenotypes of Brucella induce different intracellular trafficking and cytokine/chemokine release in human monocytes. J. Leukoc. Biol.
74: 1045-1055
[Abstract]
[Full Text]
-
Monreal, D., Grillo, M. J., Gonzalez, D., Marin, C. M., De Miguel, M. J., Lopez-Goni, I., Blasco, J. M., Cloeckaert, A, Moriyon, I.
(2003). Characterization of Brucella abortus O-Polysaccharide and Core Lipopolysaccharide Mutants and Demonstration that a Complete Core Is Required for Rough Vaccines To Be Efficient against Brucella abortus and Brucella ovis in the Mouse Model. Infect. Immun.
71: 3261-3271
[Abstract]
[Full Text]
-
Fernandez-Prada, C. M., Zelazowska, E. B., Nikolich, M., Hadfield, T. L., Roop II, R. M., Robertson, G. L., Hoover, D. L.
(2003). Interactions between Brucella melitensis and Human Phagocytes: Bacterial Surface O-Polysaccharide Inhibits Phagocytosis, Bacterial Killing, and Subsequent Host Cell Apoptosis. Infect. Immun.
71: 2110-2119
[Abstract]
[Full Text]
-
Ko, J., Splitter, G. A.
(2003). Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and Humans. Clin. Microbiol. Rev.
16: 65-78
[Abstract]
[Full Text]